Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04827992 · ClinicalTrials.gov registry record · NA

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

A NA study, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
87
Enrollment target

NCT04827992: Completed NA study, sponsored by Massachusetts General Hospital.

NCT04827992 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04827992, a NA study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
87 participants
Enrollment target

Study Summary

This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).

Primary Outcome

Median opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day, over monthly interval preceding study visit.

Interventions

  • DRUG Cannabis
  • BEHAVIORAL Prescription Opioid Taper Support (POTS)

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2021-08-23
Est. Completion 2025-10-31
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT04827992 record still lists

NCT04827992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Cannabis is the first listed.

NCT04827992 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04827992 about?

NCT04827992 is a clinical study titled "Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain". This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention...

What is the current status of trial NCT04827992?

This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2021-08-23. Estimated completion is 2025-10-31.

What interventions are being tested in trial NCT04827992?

The interventions under investigation include: Cannabis (DRUG), Prescription Opioid Taper Support (POTS) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04827992?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04827992's enrollment target sits among peer trials

87 974th of 2000 higher than 1,025 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04827992, the US trial registry maintained by the National Library of Medicine. NCT04827992 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.